NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Drug Patent Profile

When do Nicardipine Hydrochloride In 0.9% Sodium Chloride patents expire, and when can generic versions of Nicardipine Hydrochloride In 0.9% Sodium Chloride launch?

Nicardipine Hydrochloride In 0.9% Sodium Chloride is a drug marketed by Caplin, Cipla, and Hikma Intl Pharms. and is included in three NDAs.

The generic ingredient in NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nicardipine Hydrochloride In 0.9% Sodium Chloride

A generic version of NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE was approved as nicardipine hydrochloride by ANI PHARMS on October 28^th, 1996.

Summary for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	6
Clinical Trials:	59
DailyMed Link:	NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE at DailyMed

Recent Clinical Trials for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	PHASE4
Universitas Sumatera Utara	NA
VZW Cardiovascular Research Center Aalst	PHASE4

See all NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE clinical trials

Pharmacology for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Drug Class	Dihydropyridine Calcium Channel Blocker
Mechanism of Action	Calcium Channel Antagonists Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors

US Patents and Regulatory Information for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Caplin	NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	220243-001	Oct 22, 2025	AP	RX	No	No
Cipla	NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	215592-002	Sep 24, 2024	AP	RX	No	No
Caplin	NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	220243-002	Oct 22, 2025	AP	RX	No	No

Market Dynamics and Financial Trajectory for Nicardipine Hydrochloride in 0.9% Sodium Chloride

Last updated: February 10, 2026

Market Overview

Nicardipine Hydrochloride in 0.9% Sodium Chloride functions as an injectable calcium channel blocker primarily indicated for hypertensive emergencies and controlled hypotension during surgeries. The formulation's stability in sodium chloride solution enhances its use in hospitals and emergency settings. The global market for intravenous antihypertensives is expanding, driven by increasing cases of hypertension-related complications, aging populations, and rising hospital admissions.

Market Drivers

• Rising Hypertension Incidence: According to the World Health Organization (WHO), approximately 1.28 billion adults aged 30-79 worldwide have hypertension, with projections indicating continued growth. The need for effective acute blood pressure management directly fuels demand for intravenous agents like nicardipine.

• Hospitalization and Emergency Care Growth: An increased volume of ICU admissions, stroke treatments, cardiovascular surgeries, and hypertensive crises elevates usage. The global ICU market is projected to reach $101 billion by 2026, with drugs like nicardipine playing a crucial role.

• Regulatory Approvals and Off-label Use: Regulatory approvals in major markets (FDA, EMA, PMDA) ensure ongoing access. Off-label applications in neurocritical care expand market scope.

• Emergence of Generic Versions: Patent expirations for branded formulations over the next 3-5 years will enable generic manufacturers to enter, exerting downward pressure on prices but increasing overall market volume.

Market Constraints

• High Cost and Healthcare Budget Constraints: The injectable formulation’s high price limits use in low- and middle-income countries. Cost containment strategies impact adoption rates.

• Competition from Alternatives: Other antihypertensives like labetalol, clevidipine, and esmolol pose competition. The choice depends on clinical viability, safety profile, and institutional preference.

• Supply Chain Disruptions: Raw material shortages, especially of active pharmaceutical ingredients (APIs), impact production pipelines.

Market Segments and Geographies

Segment	Key Factors
Hospitals	Major end-users; steady demand
Critical Care Units	High-volume; emergencies and surgeries
Geographies	North America (largest share), Europe, Asia-Pacific, Latin America

North America held approximately 45% of the global market in 2022, driven by high healthcare spending, regulatory approvals, and clinical adoption. Asia-Pacific exhibits the fastest growth rate (CAGR 6%), fueled by expanding healthcare infrastructure and increasing hypertensive populations.

Financial Trajectory

Revenue Projections

• Global Market Revenue (2022): Estimated at $200 million.
• Forecast (2023-2028): CAGR of 5.5%, reaching approximately $270 million by 2028 [1].

Price Trends

• Per-unit Price (2022): $30–$50 per vial, with variations depending on manufacturer and region.
• Pricing Dynamics: Entry of generics expected to reduce prices by up to 30% within five years.

Key Market Players

Manufacturer	Market Share	Notable Products
Pfizer (Ichthys)	25%	Cardene IV
Bausch Health (Fresenius)	20%	Nicardipine Hydrochloride Injection
Teva Pharmaceuticals	10%	Generic versions
Others	45%	Multiple regional manufacturers

R&D Trends and Pipeline

Several companies are developing sustained-release formulations and combination therapies for hypertension and neurocritical uses, aiming to expand indications, improve patient compliance, and reduce hospital stay durations.

Regulatory and Patent Outlook

Patents for Brand Name formulations, such as Cardene IV (Pfizer), are expiring between 2023 and 2025. This transition is expected to boost generic market penetration.

Key Takeaways

• The market for nicardipine hydrochloride in saline solutions demonstrates steady growth driven by expanding hypertensive treatment needs and hospitalizations.
• Competition from generics and alternative antihypertensives influences pricing and market share.
• North America maintains dominance, while Asia-Pacific exhibits significant growth potential.
• Price erosion is expected with increased generic entry, but overall market revenue will grow due to volume increases.

---

FAQs

1. What factors influence the pricing of nicardipine hydrochloride?
Pricing is affected by manufacturing costs, regulatory approvals, competition from generics, and regional healthcare policies.

2. How does the patent landscape impact market entry?
Patent expirations for branded formulations open the market for generics, increasing supply and reducing prices over 3-5 years.

3. What is the primary clinical indication for this drug?
It is primarily used for hypertensive emergencies and during surgeries requiring controlled hypotension.

4. Which regions are experiencing the fastest market growth?
Asia-Pacific leads in growth, with a CAGR of approximately 6%, driven by increasing healthcare infrastructure and hypertensive populations.

5. How might supply chain issues affect the market?
Availability of APIs and raw materials poses risks; shortages could disrupt production and supply, impacting market stability.

---

References

[1] IQVIA. "Global Intravenous Hypertensive Agents Market Report," 2022.